[HTML][HTML] Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
[HTML][HTML] Suicide risk assessment using machine learning and social networks: a scoping review
Abstract According to the World Health Organization (WHO) report in 2016, around 800,000
of individuals have committed suicide. Moreover, suicide is the second cause of unnatural …
of individuals have committed suicide. Moreover, suicide is the second cause of unnatural …
[HTML][HTML] The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
E Terpos, M Gavriatopoulou… - Blood Cancer …, 2021 - nature.com
Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients
with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were …
with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were …
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
A Chari, MK Samur, J Martinez-Lopez… - Blood, The Journal …, 2020 - ashpublications.org
The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an
infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19 …
infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19 …
[HTML][HTML] Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma
MV Mateos, MT Hernández, P Giraldo… - … England Journal of …, 2013 - Mass Medical Soc
Background For patients with smoldering multiple myeloma, the standard of care is
observation until symptoms develop. However, this approach does not identify high-risk …
observation until symptoms develop. However, this approach does not identify high-risk …
COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
M Hultcrantz, J Richter, CA Rosenbaum, D Patel… - Blood cancer …, 2020 - AACR
Patients with multiple myeloma have a compromised immune system, due to both the
disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID …
disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID …
[HTML][HTML] Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
J Martínez-López, MV Mateos, C Encinas… - Blood cancer …, 2020 - nature.com
There is limited information on the characteristics, prognostic factors, and outcomes of
patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case …
patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case …
[HTML][HTML] Poor neutralizing antibody responses in 132 patients with CLL, NHL and HL after vaccination against SARS-CoV-2: a prospective study
Simple Summary The urgency of the COVID-19 pandemic has led to accelerated vaccine
development within less than a year. Emerging data suggest that the ability of patients with …
development within less than a year. Emerging data suggest that the ability of patients with …
Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
E Terpos, M Gavriatopoulou… - Blood, The Journal …, 2022 - ashpublications.org
The rapid development of safe and effective vaccines is imperative to attenuate the impact of
the COVID-19 pandemic. 1 Patients with multiple myeloma (MM) are at increased risk of …
the COVID-19 pandemic. 1 Patients with multiple myeloma (MM) are at increased risk of …
Treatment of multiple myeloma-related bone disease: Recommendations from the Bone Working Group of the International Myeloma Working Group
E Terpos, E Zamagni, S Lentzsch, MT Drake… - The Lancet …, 2021 - thelancet.com
Summary In this Policy Review, the Bone Working Group of the International Myeloma
Working Group updates its clinical practice recommendations for the management of …
Working Group updates its clinical practice recommendations for the management of …